| 2.212 Improved adherence to levodopa/carbidopa/entacapone (Stalevo®) or levodopa/carbidopa and entacapone as separate tablets reduces medical care utilization and costs among … T Delea, S Thomas, M Hagiwara, M Stacy Parkinsonism and Related Disorders, S100-S101, 2007 | | 2007 |
| 20 Dopamine agonists V Suski, M Stacy Handbook of Parkinson's Disease, 414, 2013 | 8 | 2013 |
| 50. Treatment patterns and patient disposition in the cervical dystonia patient registry for observation of onabotulinumtoxin A efficacy (CD PROBE) C Comella, D Charles, J Jankovic, M Stacy, M Schwartz, AM Adams, ... Toxicon, S17, 2015 | | 2015 |
| A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease M Stacy, D Silver, T Mendis, J Sutton, A Mori, P Chaikin, NM Sussman Neurology 70 (23), 2233-2240, 2008 | 196 | 2008 |
| A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease (vol 70, pg 2233, 2008) M Stacy Neurology 71 (12), 953-953, 2008 | 2 | 2008 |
| A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study Parkinson Study Group Archives of Neurology 59 (12), 1937-1943, 2002 | 695 | 2002 |
| A controlled trial of rasagiline in early Parkinson disease: The tempo study A Siderowf, M Stern, I Shoulson, K Kieburtz, D Oakes, D Day, A Shinaman, ... Archives of neurology 59 (12), 1937-1943, 2002 | 22 | 2002 |
| A haplotype at the PARK3 locus influences onset age for Parkinson’s disease: The GenePD study S Karamohamed, AL DeStefano, JB Wilk, CM Shoemaker, LI Golbe, ... Neurology 61 (11), 1557-1561, 2003 | 74 | 2003 |
| A multicenter, double-blind, placebo-controlled trial of topiramate in essential tremor J Jankovic, WG Ondo, MA Stacy, RJ Elble, R Pahwa, GS Connor, ... MOVEMENT DISORDERS 19, S448-S449, 2004 | 9 | 2004 |
| A new approach to disease-modifying drug trials in Parkinson’s disease RA Barker, M Stacy, P Brundin The Journal of Clinical Investigation 123 (6), 2364-2365, 2013 | 11 | 2013 |
| A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit MF Beal, D Oakes, I Shoulson, C Henchcliffe, WR Galpern, R Haas, ... JAMA neurology 71 (5), 543-552, 2014 | 299 | 2014 |
| AAV2-neurturin (CERE-120) and Parkinson’s disease: the safety and feasibility of combined substantia nigral and putaminal stereotactic targeting via a Phase 1/2b clinical trial … T Baumann, AE Lang, AM Lozano, CW Olanow, N Boulis, D Turner, ... Headache 21, 41.2, 2012 | 3 | 2012 |
| AAV2-neurturin (CERE-120) for Parkinson's disease P Hickey, M Stacy Expert opinion on biological therapy 13 (1), 137-145, 2013 | 27 | 2013 |
| Abnormal involuntary movement scale in tardive dyskinesia: minimal clinically important difference M Stacy, M Sajatovic, JM Kane, AJ Cutler, GS Liang, CF O'Brien, ... Movement Disorders 34 (8), 1203-1209, 2019 | 35 | 2019 |
| Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference (vol 34, pg 1203, 2019) M Stacy, M Sajatovic, JM Kane, AJ Cutler, GS Liang, CF O'Brien, ... MOVEMENT DISORDERS 34 (11), 1753-1754, 2019 | | 2019 |
| Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ‐1 (T497C) genes in familial Parkinson's disease from the … S Karamohamed, LI Golbe, MH Mark, AM Lazzarini, O Suchowersky, ... Movement disorders: official journal of the Movement Disorder Society 20 (9 …, 2005 | 27 | 2005 |
| Acknowledgment of Reviewers CLINICAL PA LeWitt, SI Deutsch, JE Ahlskog, SL Ho, W Oertel, JM Bertoni, ... NEUROPHARMACOLOGY 31 (1), 2008 | | 2008 |
| Activity enhances dopaminergic long-duration response in Parkinson disease U Jung Kang, P Auinger, S Fahn, D Oakes, I Shoulson, K Kieburtz, ... Neurology 78 (15), 1146-1149, 2012 | 36 | 2012 |
| Adenosine A2A antagonists in Parkinson’s disease: what’s next? P Hickey, M Stacy Current neurology and neuroscience reports 12, 376-385, 2012 | 77 | 2012 |
| AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study F Stocchi, O Rascol, A Destee, N Hattori, RA Hauser, AE Lang, W Poewe, ... Movement Disorders 28 (13), 1838-1846, 2013 | 148 | 2013 |
